DP303c

Clinical Trials Information Group officer

Zhang Jian

This is a study of DP303c in patients with HER2-positive advanced solid tumors.

This is a multi-center, single-arm Phase I study to evaluate the pharmacokinetic profile, safety, and initial efficacy of DP303c in patients with HER2-positive advanced solid tumors. Patients will be treated with DP303c injection at 3.0 mg/kg every 3 weeks. Patients will receive DP303c until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Trastuzumab

Vinorelbine

Antimetabolites

Antineoplastic Agents, Immunological

Tubulin Modulators

Antimitotic Agents

Eligible patients will be treated with trastuzumab IV on day 1 and oral capecitabine twice daily on days 1-14 every 3 weeks, or patients will be treated with trastuzumab IV on day 1 and vinorelbine IV over on days 1 and 8 every 3 weeks.

Vinorelbine Tartrate

Capecitabine tablets

This is a study of DP303c in patients with HER2-positive advanced breast cancer.

This is a multi-centre, randomized, open-label, controlled phase Ш clinical study to evaluate the efficacy and safety of DP303c injection versus trastuzumab combined with vinorelbine/capecitabine in the treatment of HER2-positive advanced breast cancer. Patients will be treated with DP303c injection at 3.0 mg/kg or trastuzumab combined with vinorelbine/capecitabine every 3 weeks. Patients will continue to receive treatment until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.

DP303c in Patients With HER2-positive Advanced Breast Cancer

A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303cversus Trastuzumab Combined With Vinorelbine/Capecitabine in of HER2-positive Advanced Breast Cancer

PFS is evaluated by a Blinded Independent Review Committee (BIRC) according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1.

PFS is evaluated by investigator according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1.

ORR is evaluated by investigator and BIRC according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors	NCT05810103	HER2-positive A...	DP303c	18 Years -	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
DP303c in Patients With HER2-positive Advanced Breast Cancer	NCT05901935	HER2-positive A...	DP303c Trastuzumab Vinorelbine Tar... Capecitabine ta...	18 Years -	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors	NCT05810103	HER2-positive A...	DP303c	18 Years -	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Spots Global Cancer Trial Database for dp303c

Every month we try and update this database with for dp303c cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dp303c

Every month we try and update this database with for dp303c cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dp303c cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.